Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amicus Therapeutics (FOLD) Retained Earnings (2016 - 2025)

Amicus Therapeutics (FOLD) has disclosed Retained Earnings for 16 consecutive years, with -$2.8 billion as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Retained Earnings fell 2.18% year-over-year to -$2.8 billion, compared with a TTM value of -$2.8 billion through Dec 2025, down 2.18%, and an annual FY2025 reading of -$2.8 billion, down 2.18% over the prior year.
  • Retained Earnings was -$2.8 billion for Q4 2025 at Amicus Therapeutics, down from -$2.8 billion in the prior quarter.
  • Across five years, Retained Earnings topped out at -$2.1 billion in Q1 2021 and bottomed at -$2.8 billion in Q3 2024.
  • Average Retained Earnings over 5 years is -$2.6 billion, with a median of -$2.6 billion recorded in 2023.
  • The sharpest move saw Retained Earnings decreased 13.39% in 2022, then rose 1.11% in 2025.
  • Year by year, Retained Earnings stood at -$2.3 billion in 2021, then fell by 10.3% to -$2.5 billion in 2022, then fell by 5.99% to -$2.7 billion in 2023, then dropped by 2.09% to -$2.7 billion in 2024, then decreased by 2.18% to -$2.8 billion in 2025.
  • Business Quant data shows Retained Earnings for FOLD at -$2.8 billion in Q4 2025, -$2.8 billion in Q3 2025, and -$2.8 billion in Q2 2025.